What does 'triple-positive' APS mean and why does it change management?

Triple-positive APS means all three aPL tests are positive simultaneously: lupus anticoagulant (LA), anticardiolipin antibodies IgG/IgM (aCL), and anti-β2-glycoprotein-1 IgG/IgM (anti-β2GP1). This combination carries the highest thrombosis risk — approximately 10–12% per year for a first clot and higher for recurrence. For triple-positive APS after any venous or arterial event, warfarin with a target INR of 2–3 (arterial or recurrent: INR 3–4 in some centres) is standard. The TRAPS trial (New England Journal of Medicine, 2018) randomised high-risk APS patients (all triple-positive) to rivaroxaban versus warfarin and stopped early because rivaroxaban caused significantly more thromboembolic events and major bleeding — a finding that generalises to all DOACs, making them contraindicated in high-risk APS. Single-positive or double-positive aPL with no prior clot may not require anticoagulation, and haematology or rheumatology review should guide that decision.

How does aspirin plus heparin help in obstetric APS?

In obstetric APS, aPL antibodies bind to phospholipid-binding proteins on placental trophoblasts, triggering complement activation and impairing the placentation that supports a healthy pregnancy. Without treatment, recurrent miscarriage rates are approximately 70% and some women experience stillbirth or severe early-onset pre-eclampsia. Aspirin 100 mg daily is started before conception (or from the first positive pregnancy test), and LMWH is added from a positive βhCG — typically enoxaparin 40 mg subcutaneously once daily (prophylactic dose) for most obstetric criteria APS. Aspirin is continued to 36 weeks; LMWH stops 24 hours before delivery and restarts postnatally for 6–12 weeks. The Empson Cochrane systematic review (2005) demonstrated this combination improved live-birth rates from roughly 30% to 70–80%. Women with prior thrombotic APS during pregnancy may need therapeutic LMWH — specialist collaboration is essential. LMWH is not listed on the PBS for this indication so out-of-pocket cost needs discussion.

What is catastrophic APS and how is it different from ordinary APS?

Catastrophic antiphospholipid syndrome (CAPS) — also called Asherson syndrome — is a rare but life-threatening variant characterised by simultaneous thrombosis in three or more organ systems developing over hours to days (unlike the episodic single-organ events of standard APS). Kidneys, lungs, and brain are most often affected; the skin shows livedo racemosa, purpura, or digital ischaemia. Mortality is approximately 30%, typically from multi-organ failure or haemorrhage. CAPS accounts for fewer than 1% of all APS cases but requires immediate recognition and transfer to intensive care. Treatment is triple therapy in parallel: therapeutic anticoagulation (IV unfractionated heparin), high-dose methylprednisolone (1 g IV daily for 3 days), plus plasma exchange or IVIG. An international CAPS registry (Cervera, 2010) informed current management consensus. Triggers include infection, surgery, anticoagulation withdrawal, and in about 25% of cases no trigger is identified.

When should I repeat the aPL tests, and what counts as 'positive'?

A single positive aPL result is not diagnostic — the test must be positive on **two separate occasions at least 12 weeks apart** to confirm true persistence. This requirement exists because transient aPL positivity occurs with acute infections (especially COVID-19, EBV, CMV, and bacterial sepsis) and does not carry long-term thrombotic risk. The 2006 Sapporo/Sydney criteria and updated 2023 ACR/EULAR APS classification criteria both require this 12-week confirmation. Tests to request: (1) lupus anticoagulant — detected by clotting-based assays (dRVVT + silica clotting time), (2) aCL IgG and IgM (ELISA, > 40 GPL or MPL units or > 99th percentile), and (3) anti-β2GP1 IgG and IgM (> 99th percentile). For GP billing: lupus anticoagulant is on Medicare MBS Item 65120; aCL and anti-β2GP1 are on Items 71146 and 71148. Repeat testing at 12+ weeks before committing to indefinite anticoagulation is both good medicine and good stewardship.

Should I stop oestrogen contraception or HRT in a woman with APS?

Yes — combined oestrogen-containing preparations are contraindicated in APS. Oestrogen amplifies the prothrombotic effect of aPL antibodies by upregulating tissue factor, activating protein C resistance, and altering coagulation factor synthesis. For contraception, the copper IUD (non-hormonal) or a progestogen-only method is preferred; the Mirena IUS (levonorgestrel-only, negligible systemic absorption) is generally considered acceptable — discuss with the haematologist or rheumatologist managing the APS. For perimenopause, non-hormonal strategies (SSRIs for vasomotor symptoms, phytoestrogens with appropriate caveats) or very low-dose transdermal oestrogen with dedicated thrombosis risk counselling may be considered only if APS is well-controlled and single-positive at low titre — this is a specialist decision, not a GP decision. The ACR/EULAR 2023 guidance and Australian consensus (ANZSBT/RACP) both caution against oestrogen in symptomatic APS.

Antiphospholipid syndrome (thrombotic and obstetric)

Antiphospholipid syndrome: warfarin not DOACs, LMWH in pregnancy

By Dr HB Lo, FACRRM Reviewed 16 September 2026 9 min read

Antiphospholipid syndrome (APS) is an autoimmune thrombophilia driven by persistent antiphospholipid antibodies that promote arterial, venous, and placental clotting. In triple-positive APS, warfarin (INR 2–3) is required — DOACs are inferior and significantly raise stroke risk (TRAPS trial, NEJM 2018). For obstetric APS (recurrent pregnancy loss), aspirin 100 mg daily plus LMWH from the first positive pregnancy test recovers live-birth rates from ~30% to 70–80% (Empson Cochrane 2005). Catastrophic APS — simultaneous multi-organ thrombosis over hours — carries ~30% mortality and requires emergency triple therapy: anticoagulation, high-dose methylprednisolone, and plasma exchange or IVIG.

Antiphospholipid syndrome (APS) is one of the most underdiagnosed causes of otherwise-unexplained stroke in people under 50, recurrent pregnancy loss, and unprovoked venous thromboembolism (VTE). It is also one of the most treatable — but only if the correct anticoagulant is used. In high-risk (triple-positive) APS, DOACs are not safe; warfarin is not optional. In obstetric APS, aspirin plus LMWH from the first positive pregnancy test changes the prognosis from approximately 30% live birth to 70–80%.

This guide is written for Australian general practitioners managing people with known or suspected APS or their referral partners.

A. Core clinical — what every GP needs to know immediately

What antiphospholipid syndrome is

APS is a systemic autoimmune condition in which persistent antiphospholipid antibodies (aPL) — lupus anticoagulant (LA), anticardiolipin (aCL IgG/IgM), and anti-β2-glycoprotein-1 (anti-β2GP1 IgG/IgM) — promote pathological clotting and/or pregnancy complications. aPL antibodies bind to phospholipid-binding proteins on cell membranes, activating complement, platelets, and endothelium.

Two clinical phenotypes:

Thrombotic APS — arterial or venous thrombosis not fully explained by other risk factors, confirmed alongside aPL persistence.
Obstetric APS — recurrent early pregnancy loss (≥3 before 10 weeks), ≥1 foetal loss after 10 weeks, or severe early-onset pre-eclampsia or placental insufficiency before 34 weeks.

Both phenotypes can coexist, and an individual can present with one then develop the other.

The antibody profile matters: triple-positive = highest risk

Antibody profile	Annual thrombosis risk (approximate)	Management implication
Single positive, low titre	~2–4% first event	Consider aspirin; anticoagulation after event
Double positive	~5–7% first event	Anticoagulate after first event
Triple positive (LA + aCL + anti-β2GP1)	~10–12% first event; high recurrence	Indefinite warfarin; DOACs contraindicated

The triple-positive profile is the clearest evidence for life-long warfarin. In the TRAPS trial (Pengo, NEJM 2018), triple-positive patients on rivaroxaban had significantly higher rates of thromboembolic events and major bleeding than those on warfarin, leading to early trial cessation.

The diagnostic threshold: two positive tests ≥ 12 weeks apart

Transient aPL positivity is common with acute infections (COVID-19, EBV, CMV, bacterial sepsis). A single positive result does not establish APS — the 2006 Sapporo/Sydney criteria and 2023 ACR/EULAR classification criteria both require:

Positive test on two separate occasions, at least 12 weeks apart
Clinical criterion (thrombosis or pregnancy morbidity) also present

Do not start indefinite anticoagulation on a first positive result. Repeat at 12 weeks.

Initial GP assessment

When APS is suspected — e.g., unprovoked DVT or PE in a young patient, arterial stroke without conventional risk factors, recurrent miscarriage — request:

Lupus anticoagulant (dRVVT + silica clotting time) — MBS Item 65120
aCL IgG and IgM (ELISA > 40 GPL/MPL or > 99th percentile) — MBS Item 71146
Anti-β2GP1 IgG and IgM (> 99th percentile) — MBS Item 71148
Full blood count (thrombocytopenia occurs in ~20–30%), ANA (screen for concurrent SLE), ESR, CRP, renal function

Note: warfarin can artificially elevate LA tests; ideally draw before anticoagulation is started. Discuss timing with the treating haematologist.

B. Evidence behind the key recommendations

Warfarin versus DOACs in thrombotic APS

The TRAPS trial (Pengo et al., NEJM 2018) is the pivotal study. Randomised, open-label, non-inferiority trial in triple-positive APS patients comparing rivaroxaban 20 mg daily versus warfarin (INR 2–3). Stopped early after enrolling 120 patients: rivaroxaban arm had 12 thromboembolic or major bleeding events versus 0 in the warfarin arm (RR numerically very high; non-inferiority not met). Similar signals emerged from the ASTRO-APS (apixaban) pilot and the RAPS trial (rivaroxaban in lower-risk single-positive APS).

Mechanism: DOACs inhibit a single coagulation factor (Xa or IIa). APS-mediated thrombosis involves multiple pathways — complement activation, platelet activation, TLR activation, and NET formation — that are not adequately suppressed by factor Xa inhibition alone. Warfarin, by depleting multiple vitamin-K-dependent factors (II, VII, IX, X), provides broader suppression.

Target INR:

Standard thrombotic APS (venous): INR 2–3
Arterial events or recurrent thrombosis despite INR 2–3: INR 2.5–3.5 (some centres 3–4 with haematology input)
Obstetric APS without prior thrombosis: aspirin ± LMWH only (no warfarin during pregnancy — teratogenic)

Aspirin plus LMWH in obstetric APS

Empson et al. (Cochrane systematic review, 2005) — aspirin 75–100 mg daily plus heparin (LMWH or unfractionated) significantly reduced pregnancy loss in confirmed obstetric APS compared with aspirin alone (RR 0.46, 95% CI 0.29–0.71). Live-birth rates improved from approximately 30% to 70–80%. The mechanism involves both anticoagulant and anti-complement effects on placental trophoblasts.

LMWH preferred over unfractionated heparin for subcutaneous ease, predictable dosing, and lower heparin-induced thrombocytopenia (HIT) risk. Note: LMWH is not PBS-subsidised for obstetric APS; patients pay out of pocket (~$1.50–$3.00/day enoxaparin).

CAPS triple therapy

Cervera et al. (CAPS Registry, 2009) — among 280 CAPS patients, triple therapy (anticoagulation + corticosteroids + plasma exchange or IVIG) had significantly lower mortality than any doublet or monotherapy (29% versus 42–54%). No randomised controlled trials exist (condition too rare); registry data and consensus guide management.

C. Anticoagulation in specific situations

First unprovoked VTE, low-risk single-positive aPL

The risk–benefit calculation for indefinite versus time-limited anticoagulation depends on antibody titre and profile. A low-titre, single-positive aCL after a first unprovoked DVT with no other APS features may be managed as standard VTE (3–6 months), then reassessed with repeat aPL at 12 weeks. This decision requires haematology review; do not make it in isolation.

Warfarin and pregnancy

Warfarin is teratogenic (embryopathy risk 5–10% in first trimester) and causes foetal haemorrhage. Switch to LMWH before conception — plan this proactively with the woman before she attempts pregnancy. Haematology and obstetrics collaboration is essential. After delivery, warfarin is safe in breastfeeding (does not pass into breast milk in significant quantities; AMH and eTG concur).

Intercurrent acute illness, surgery, or anticoagulation interruption

Anticoagulation interruption is a recognised trigger for CAPS. Where possible, bridge with LMWH during surgical procedures rather than stopping anticoagulation cold. Emergency surgery with active anticoagulation needs haematology input. Patient-held anticoagulation cards are recommended so any emergency clinician is aware.

APS in SLE

Approximately 20–30% of people with systemic lupus erythematosus (SLE) have concurrent aPL; ~50% of lupus patients with stroke have APS. Combined SLE + APS has additive cardiovascular risk. Hydroxychloroquine (used in SLE) has independent aPL-reducing and antithrombotic effects — it is generally continued in SLE-APS. Management is shared between rheumatology and haematology.

D. Australian clinical operations

MBS items for GP billing

Service	Item	Notes
Lupus anticoagulant	65120	dRVVT + confirmatory assay
aCL IgG/IgM	71146	ELISA
Anti-β2GP1 IgG/IgM	71148	ELISA
INR monitoring	65070	In-office point-of-care INR
Long consultation (INR review + management)	23 or 36	As appropriate

PBS anticoagulants

Warfarin — PBS General Schedule (low cost, patient access straightforward).
Enoxaparin (LMWH) — PBS-listed for VTE treatment and prevention; obstetric APS is not an approved PBS indication. Discuss cost with patients early; some private health insurers may assist.
Fondaparinux — for heparin allergy; PBS-listed for some VTE indications.

Avoiding oestrogen

In any woman of reproductive age with confirmed APS or high-titre aPL positivity:

Cease combined oral contraceptive pill and oestrogen-containing vaginal rings.
Discuss copper IUD (Paragard — not PBS-subsidised; GPs can apply for authority items through local pathways) or Mirena IUS (levonorgestrel-only, generally acceptable) or progestogen-only pill (mini-pill, PBS Item).
Document the contraception switch and reason in the medical record.

Haematology/rheumatology referral pathways

First confirmed APS (especially triple-positive, first thrombosis, first obstetric APS): haematology or rheumatology consultation — Category 2 referral (seen within 90 days for stable outpatients; Category 1 for recent thrombosis).
CAPS: immediate emergency referral / 000 call / ICU transfer.
In rural or remote settings: telehealth haematology consultations are available through state-based clinical networks; RACP and ASUM telehealth pathways apply.

E. Special populations

Adolescents and young adults with first stroke

APS is among the most important causes of stroke in people under 50 without conventional risk factors. Any ischaemic stroke in someone under 50 should include aPL screening as part of the workup, alongside cardiac embolism screen, thrombophilia panel, and vasculitis screen. Neurology-haematology co-management is standard.

Recurrent pregnancy loss — where does APS fit?

Recurrent miscarriage (≥3 consecutive losses before 10 weeks, or ≥1 after 10 weeks) has many causes: chromosomal (50–60% of early losses), uterine structural, endocrine (thyroid), and antiphospholipid (found in 5–15% of recurrent miscarriage cases). Testing for APS is part of the recurrent pregnancy loss workup (RANZCOG guidelines). The aPL panel should be requested alongside karyotype of products of conception, pelvic ultrasound, thyroid function, and prolactin.

Elderly patients on warfarin for APS

Warfarin in older patients requires careful monitoring for falls (consider if INR 2–3 is achievable safely) and drug interactions (increased with many antibiotics, antifungals). Warfarin cannot be replaced with a DOAC in confirmed APS — the clinical risk of doing so outweighs the inconvenience of INR monitoring. Discuss with haematology before any regimen change. Monthly INR monitoring in stable patients is sufficient; point-of-care testing (Item 65070) or home INR monitoring (HeMaIL program — [haematology centres]) may be available.

Thrombocytopenia in APS

Mild-to-moderate thrombocytopenia (platelets 80–150 × 10⁹/L) is common in APS and does not usually contraindicate anticoagulation. Very low platelets (< 50 × 10⁹/L) require haematology review before any anticoagulation decision.

When to escalate

Call 000 immediately:

Any features of CAPS — rapidly developing multi-organ failure, new renal impairment, respiratory distress, new neurological symptoms, skin purpura or digital ischaemia over hours to days.
Acute arterial thrombosis (limb, mesenteric, stroke).

Same-day emergency review:

Sudden swelling, warmth, and pain in a limb (DVT) in a known APS patient — do not delay assessment pending imaging.
Supratherapeutic INR with bleeding.

Urgent (within days) specialist referral:

First confirmed triple-positive APS after recent thrombosis.
aPL positive plus early/recurrent pregnancy loss — refer to haematology or obstetric medicine before next planned pregnancy.
Possible APS in a patient already on a DOAC — review and potential switch to warfarin.

Routine referral:

Single-positive aPL found incidentally, no history of thrombosis — follow-up aPL at 12 weeks, then haematology if persistent.

What this article is and is not

This article is an evidence-based educational summary for Australian general practitioners, drawing on eTG, AMH, ANZSBT guidelines, RANZCOG guidelines, and international peer-reviewed literature. It is written to help GPs understand the clinical approach to APS and identify when to refer.

This article does not replace a formal medical consultation, nor does it substitute for the judgment of a haematologist or rheumatologist managing complex cases. Dosing and management decisions should be individualised to the patient. Drug information is current at date of publication; always verify doses and indications in current eTG or AMH before prescribing.

No individual is mentioned in this article, and no personal testimonials are cited.

Sources cited

eTG — Anticoagulation and antithrombotic therapy (APS section). Therapeutic Guidelines Limited. tg.org.au
AMH — Antiphospholipid syndrome. Australian Medicines Handbook. amhonline.amh.net.au
Pengo V et al. (TRAPS trial). Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. NEJM 2018;378:2011–2021. nejm.org
Empson M et al. Recurrent pregnancy loss with antiphospholipid antibody: systematic review. Cochrane Database Syst Rev 2005. cochranelibrary.com
Barbhaiya M et al. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol 2023;75:1687–1702. acrjournals.onlinelibrary.wiley.com
Miyakis S et al. International consensus statement: Sapporo/Sydney criteria for APS. J Thromb Haemost 2006;4:295–306. onlinelibrary.wiley.com
Cervera R et al. Catastrophic antiphospholipid syndrome (CAPS Registry). J Autoimmun 2009;32:240–245. sciencedirect.com
ANZSBT — Guidelines for antiphospholipid antibody testing and management. anzsbt.org.au
RANZCOG — Clinical guidelines on thrombosis in pregnancy including APS. ranzcog.edu.au
Healthdirect — Antiphospholipid syndrome. healthdirect.gov.au
Better Health Channel — Antiphospholipid syndrome. betterhealth.vic.gov.au
Lupus Australia — APS patient information. lupusaustralia.com.au
MBS Online — Items 65120, 71146, 71148 (aPL testing). mbsonline.gov.au

Frequently asked questions

What does 'triple-positive' APS mean and why does it change management?

Triple-positive APS means all three aPL tests are positive simultaneously: lupus anticoagulant (LA), anticardiolipin antibodies IgG/IgM (aCL), and anti-β2-glycoprotein-1 IgG/IgM (anti-β2GP1). This combination carries the highest thrombosis risk — approximately 10–12% per year for a first clot and higher for recurrence. For triple-positive APS after any venous or arterial event, warfarin with a target INR of 2–3 (arterial or recurrent: INR 3–4 in some centres) is standard. The TRAPS trial (New England Journal of Medicine, 2018) randomised high-risk APS patients (all triple-positive) to rivaroxaban versus warfarin and stopped early because rivaroxaban caused significantly more thromboembolic events and major bleeding — a finding that generalises to all DOACs, making them contraindicated in high-risk APS. Single-positive or double-positive aPL with no prior clot may not require anticoagulation, and haematology or rheumatology review should guide that decision.
How does aspirin plus heparin help in obstetric APS?

In obstetric APS, aPL antibodies bind to phospholipid-binding proteins on placental trophoblasts, triggering complement activation and impairing the placentation that supports a healthy pregnancy. Without treatment, recurrent miscarriage rates are approximately 70% and some women experience stillbirth or severe early-onset pre-eclampsia. Aspirin 100 mg daily is started before conception (or from the first positive pregnancy test), and LMWH is added from a positive βhCG — typically enoxaparin 40 mg subcutaneously once daily (prophylactic dose) for most obstetric criteria APS. Aspirin is continued to 36 weeks; LMWH stops 24 hours before delivery and restarts postnatally for 6–12 weeks. The Empson Cochrane systematic review (2005) demonstrated this combination improved live-birth rates from roughly 30% to 70–80%. Women with prior thrombotic APS during pregnancy may need therapeutic LMWH — specialist collaboration is essential. LMWH is not listed on the PBS for this indication so out-of-pocket cost needs discussion.
What is catastrophic APS and how is it different from ordinary APS?

Catastrophic antiphospholipid syndrome (CAPS) — also called Asherson syndrome — is a rare but life-threatening variant characterised by simultaneous thrombosis in three or more organ systems developing over hours to days (unlike the episodic single-organ events of standard APS). Kidneys, lungs, and brain are most often affected; the skin shows livedo racemosa, purpura, or digital ischaemia. Mortality is approximately 30%, typically from multi-organ failure or haemorrhage. CAPS accounts for fewer than 1% of all APS cases but requires immediate recognition and transfer to intensive care. Treatment is triple therapy in parallel: therapeutic anticoagulation (IV unfractionated heparin), high-dose methylprednisolone (1 g IV daily for 3 days), plus plasma exchange or IVIG. An international CAPS registry (Cervera, 2010) informed current management consensus. Triggers include infection, surgery, anticoagulation withdrawal, and in about 25% of cases no trigger is identified.
When should I repeat the aPL tests, and what counts as 'positive'?

A single positive aPL result is not diagnostic — the test must be positive on **two separate occasions at least 12 weeks apart** to confirm true persistence. This requirement exists because transient aPL positivity occurs with acute infections (especially COVID-19, EBV, CMV, and bacterial sepsis) and does not carry long-term thrombotic risk. The 2006 Sapporo/Sydney criteria and updated 2023 ACR/EULAR APS classification criteria both require this 12-week confirmation. Tests to request: (1) lupus anticoagulant — detected by clotting-based assays (dRVVT + silica clotting time), (2) aCL IgG and IgM (ELISA, > 40 GPL or MPL units or > 99th percentile), and (3) anti-β2GP1 IgG and IgM (> 99th percentile). For GP billing: lupus anticoagulant is on Medicare MBS Item 65120; aCL and anti-β2GP1 are on Items 71146 and 71148. Repeat testing at 12+ weeks before committing to indefinite anticoagulation is both good medicine and good stewardship.
Should I stop oestrogen contraception or HRT in a woman with APS?

Yes — combined oestrogen-containing preparations are contraindicated in APS. Oestrogen amplifies the prothrombotic effect of aPL antibodies by upregulating tissue factor, activating protein C resistance, and altering coagulation factor synthesis. For contraception, the copper IUD (non-hormonal) or a progestogen-only method is preferred; the Mirena IUS (levonorgestrel-only, negligible systemic absorption) is generally considered acceptable — discuss with the haematologist or rheumatologist managing the APS. For perimenopause, non-hormonal strategies (SSRIs for vasomotor symptoms, phytoestrogens with appropriate caveats) or very low-dose transdermal oestrogen with dedicated thrombosis risk counselling may be considered only if APS is well-controlled and single-positive at low titre — this is a specialist decision, not a GP decision. The ACR/EULAR 2023 guidance and Australian consensus (ANZSBT/RACP) both caution against oestrogen in symptomatic APS.

Source quality

Sources grouped by evidence tier. AU primary tier first; international where AU is silent or lagging; named-author reconstruction where guidelines have not yet caught up. How tiers work.